| 商品名称 | Sitagliptin Accord |
|---|
| 适用类别 | Human |
|---|
| 治疗领域 | Diabetes Mellitus, Type 2 |
|---|
| 通用名/非专利名称 | sitagliptin |
|---|
| 活性成分 | sitagliptin hydrochloride |
|---|
| 产品号 | EMEA/H/C/005598 |
|---|
| 患者安全信息 | No |
|---|
| 许可状态 | Authorised |
|---|
| ATC编码 | A10BH01 |
|---|
| 是否额外监管 | No |
|---|
| 是否仿制药或hybrid药物 | Yes |
|---|
| 是否生物类似药 | No |
|---|
| 是否附条件批准 | No |
|---|
| 是否特殊情形 | No |
|---|
| 是否加速审评 | No |
|---|
| 是否罕用药 | No |
|---|
| 上市许可日期 | 2022/04/25 |
|---|
| 上市许可开发者/申请人/持有人 | Accord Healthcare S.L.U. |
|---|
| 人用药物治疗学分组 | Drugs used in diabetes |
|---|
| 兽用药物治疗学分组 | |
|---|
| 审评意见日期 | 2022/02/24 |
|---|
| 欧盟委员会决定日期 | 2025/01/24 |
|---|
| 修订号 | 1 |
|---|
| 治疗适应症 | For adult patients with type 2 diabetes mellitus, Sitagliptin Accord is indicated to improve glycaemic control: as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control.- a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance.- a peroxisome proliferator-activated receptor gamma (PPARy) agonist (i.e. a thiazolidinedione) when use of a PPARy agonist is appropriate and when diet and exercise plus the PPARy agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.- a PPARy agonist and metformin when use of a PPARy agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. Sitagliptin Accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control. |
|---|
| 适用物种 | |
|---|
| 兽用药物ATC编码 | |
|---|
| 首次发布日期 | 2022/02/22 |
|---|
| 最后更新日期 | 2025/01/27 |
|---|
| 产品说明书 | https://www.ema.europa.eu/en/documents/product-information/sitagliptin-accord-epar-product-information_en.pdf |
|---|
| 公共评估报告 | https://www.ema.europa.eu/en/medicines/human/EPAR/sitagliptin-accord |
|---|